Welcome to our dedicated page for Verona Pharma news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma stock.
Verona Pharma PLC (VRNA) is a clinical-stage biopharmaceutical company advancing innovative therapies for chronic respiratory diseases. This page serves as the definitive source for official news, including updates on clinical trials, regulatory milestones, and strategic partnerships.
Investors and researchers can track developments related to key programs like ensifentrine for COPD treatment, with real-time access to press releases about FDA submissions, trial results, and manufacturing collaborations. Our curated collection ensures you never miss critical updates about respiratory therapy innovations.
Explore verified information on phase III trial progress, regulatory communications, and research partnerships with leading medical institutions. All content is sourced directly from company filings and official statements to maintain accuracy.
Bookmark this page for streamlined access to VRNA's latest advancements in treating COPD, cystic fibrosis, and asthma. Check regularly for developments that shape the future of respiratory care.
Verona Pharma (Nasdaq: VRNA), a clinical-stage biopharmaceutical company, will announce its financial results for the first quarter ended March 31, 2023, on May 9, 2023. The company will host a conference call at 9:00 a.m. EDT to discuss the results and provide a corporate update. Participants can join the call by dialing +1-833-816-1396 for US callers or +1-412-317-0489 for international callers. A live webcast will also be available on their Investors page. Verona Pharma is focused on developing innovative therapies for chronic respiratory diseases. Their product candidate, ensifentrine, aims to combine bronchodilator and anti-inflammatory activities and has shown positive results in Phase 3 trials.
Verona Pharma plc (Nasdaq: VRNA) has announced that its development partner, Nuance Pharma, has begun dosing participants in the ENHANCE - China Phase 3 trial for ensifentrine, aimed at treating chronic obstructive pulmonary disease (COPD). This milestone follows the clearance of an Investigational New Drug application by the Center of Drug Evaluation in August 2022. Ensifentrine has shown promising results in prior Phase 3 trials, demonstrating significant improvements in lung function and reduced COPD exacerbations. Up to $179 million in milestone payments plus royalties are anticipated from Nuance Pharma's commercialization efforts in Greater China. An NDA for ensifentrine is expected to be submitted to the FDA in Q2 2023, reflecting Verona's commitment to addressing unmet needs in respiratory disease treatment.
Nuance Pharma has initiated dosing for the first patient in the ENHANCE - China Phase III Trial, focusing on the maintenance treatment of chronic obstructive pulmonary disease (COPD) using Ensifentrine. This innovative drug is a first-in-class dual inhibitor of phosphodiesterase enzymes, which combines bronchodilation and anti-inflammatory effects. The trial represents a significant advancement in Nuance Pharma's collaboration with Verona Pharma, which recently reported positive outcomes from previous Phase III trials. Ensifentrine aims to deliver substantial improvements in lung function and quality of life for COPD patients. Verona Pharma plans to submit a New Drug Application to the FDA in Q2 2023 for Ensifentrine following these promising results.
FAQ
What is the current stock price of Verona Pharma (VRNA)?
What is the market cap of Verona Pharma (VRNA)?
